Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Eva Kaliskova"'
Autor:
Irena Hanovcova, Patricia Lommel, Eva Kaliskova, Jitka Motlova, Roman Prymula, Vera Lebedova, Splino M, Dorota Borys, Thierry G. Pascal, Lode Schuerman, Pavla Kriz
Publikováno v:
Vaccine. 29(10)
Pneumococcal conjugate vaccines (PCV) may reduce nasopharyngeal carriage (NPC) of Streptococcus pneumoniae vaccine strains (VT), but serotype replacement with non-vaccine strains (NVT) has been reported. Bacterial NPC after PHiD-CV vaccination was as
Autor:
Patricia Lommel, Eva Kaliskova, Marie Vacková, Claire-Anne Siegrist, Jan Smetana, Roman Prymula, Roman Chlibek, Lode Schuerman, Dorota Borys, Helena Zemlickova
Publikováno v:
ResearcherID
The Lancet, Vol. 374, No 9698 (2009) pp. 1339-1350
The Lancet, Vol. 374, No 9698 (2009) pp. 1339-1350
BACKGROUND: Although fever is part of the normal inflammatory process after immunisation, prophylactic antipyretic drugs are sometimes recommended to allay concerns of high fever and febrile convulsion. We assessed the effect of prophylactic administ
Publikováno v:
Vaccine. 28(1)
Following primary and booster vaccination with an 11-valent pneumococcall protein D conjugate vaccine there was a 42.8% (95% CI: −16.7 to 71.9, ns) reduction in the carriage of Streptococcus pneumoniae vaccine serotypes and a 42.6% (95% CI: 1.3–6
Autor:
Veronika Wertzova, Jeanne-Marie Devaster, Pascale Van Belle, Eva Kaliskova, Bruce L. Innis, Helena Jirincova, Jiří Beran, Martina Havlíčková, Jiří Havlík, Karel Honegr, Varsha K. Jain
Publikováno v:
BMC Infectious Diseases, Vol 9, Iss 1, p 2 (2009)
BMC Infectious Diseases
BMC Infectious Diseases
Background Our aim was to determine the efficacy of a trivalent inactivated split virus influenza vaccine (TIV) against culture-confirmed influenza A and/or B in adults 18 to 64 years of age during the 2005/2006 season in the Czech Republic. Methods
Autor:
Igor Kohl, Roman Prymula, Splino M, Patricia Lommel, Eva Kaliskova, Roman Chlibek, Lode Schuerman
Publikováno v:
Vaccine. 26(35)
This randomized (1:1), double-blind, multicenter study, included 4,968 healthy infants to receive either the 11-valent pneumococcal protein D (PD)-conjugate study vaccine or the hepatitis A vaccine (HAV) (control) at 3, 4, 5, and 12-15 months of age.